Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 105 | 0.750 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2019 | 20 | 0.710 |
Why?
|
| Arabinonucleosides | 2 | 2021 | 4 | 0.500 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 99 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2017 | 15 | 0.470 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2017 | 24 | 0.340 |
Why?
|
| Burkitt Lymphoma | 2 | 2021 | 5 | 0.340 |
Why?
|
| Adenine Nucleotides | 1 | 2010 | 1 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 86 | 0.320 |
Why?
|
| Arsenicals | 2 | 2007 | 6 | 0.310 |
Why?
|
| Oxides | 2 | 2007 | 7 | 0.310 |
Why?
|
| Cranial Irradiation | 2 | 2007 | 6 | 0.310 |
Why?
|
| Humans | 24 | 2022 | 12240 | 0.290 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 7 | 0.280 |
Why?
|
| Middle Aged | 14 | 2022 | 4043 | 0.280 |
Why?
|
| Cachexia | 2 | 2019 | 8 | 0.270 |
Why?
|
| Rituximab | 7 | 2021 | 19 | 0.260 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2007 | 1 | 0.260 |
Why?
|
| Ear Neoplasms | 1 | 2007 | 3 | 0.260 |
Why?
|
| Sarcoma, Myeloid | 1 | 2007 | 4 | 0.250 |
Why?
|
| Male | 14 | 2022 | 6815 | 0.250 |
Why?
|
| Adult | 10 | 2021 | 3557 | 0.230 |
Why?
|
| Female | 14 | 2021 | 6974 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2008 | 27 | 0.220 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2003 | 2 | 0.200 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 35 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 3 | 2008 | 7 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2021 | 66 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 6 | 0.180 |
Why?
|
| Aged | 9 | 2021 | 4000 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 20 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 6 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 42 | 0.170 |
Why?
|
| Thrombosis | 1 | 2021 | 33 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2152 | 0.170 |
Why?
|
| Cyclophosphamide | 5 | 2021 | 22 | 0.160 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2020 | 1 | 0.160 |
Why?
|
| Benzylidene Compounds | 1 | 2020 | 1 | 0.160 |
Why?
|
| Azepines | 1 | 2020 | 2 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 7 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 31 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 34 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 4 | 0.150 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 57 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2021 | 1478 | 0.150 |
Why?
|
| Paraproteinemias | 1 | 2019 | 2 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 41 | 0.140 |
Why?
|
| Doxorubicin | 4 | 2021 | 34 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2019 | 31 | 0.140 |
Why?
|
| Remission Induction | 4 | 2007 | 45 | 0.140 |
Why?
|
| HIV Infections | 1 | 2021 | 256 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2018 | 23 | 0.140 |
Why?
|
| Cardiology | 1 | 2018 | 26 | 0.140 |
Why?
|
| Vincristine | 4 | 2017 | 15 | 0.120 |
Why?
|
| Recurrence | 2 | 2020 | 126 | 0.120 |
Why?
|
| Prednisone | 4 | 2017 | 31 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 363 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 69 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 40 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 82 | 0.100 |
Why?
|
| Obesity | 1 | 2014 | 156 | 0.100 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2012 | 1 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2008 | 28 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 143 | 0.080 |
Why?
|
| Retreatment | 1 | 2010 | 3 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2010 | 7 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 10 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 423 | 0.070 |
Why?
|
| Weight Loss | 2 | 2019 | 78 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 827 | 0.070 |
Why?
|
| Daunorubicin | 1 | 2007 | 3 | 0.060 |
Why?
|
| Tretinoin | 1 | 2007 | 8 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2007 | 16 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 8 | 0.060 |
Why?
|
| Young Adult | 2 | 2021 | 863 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 258 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 51 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 85 | 0.050 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 3 | 0.050 |
Why?
|
| Thalidomide | 1 | 2004 | 3 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 10 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 1 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 105 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2003 | 3 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 3 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 5 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2003 | 8 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 22 | 0.050 |
Why?
|
| Methotrexate | 1 | 2003 | 18 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 151 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 2 | 0.050 |
Why?
|
| K562 Cells | 1 | 2003 | 4 | 0.050 |
Why?
|
| Histones | 1 | 2003 | 13 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2006 | 385 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2019 | 1467 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 77 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 1 | 0.050 |
Why?
|
| Voriconazole | 1 | 2022 | 7 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2022 | 22 | 0.040 |
Why?
|
| Cytosine | 1 | 2021 | 2 | 0.040 |
Why?
|
| Azacitidine | 1 | 2021 | 9 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 464 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 29 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 3 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 247 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 5 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 8 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 31 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 93 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 15 | 0.040 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 2 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 4 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 10 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 10 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 15 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 99 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 36 | 0.040 |
Why?
|
| Body Composition | 1 | 2019 | 43 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 97 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 59 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 9 | 0.030 |
Why?
|
| Cardiologists | 1 | 2018 | 2 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 229 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 989 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 94 | 0.030 |
Why?
|
| Bortezomib | 1 | 2017 | 3 | 0.030 |
Why?
|
| United States | 1 | 2021 | 989 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 294 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 161 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 90 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 23 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 19 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 246 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 2092 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cytarabine | 1 | 2007 | 5 | 0.020 |
Why?
|
| Etoposide | 1 | 2007 | 15 | 0.020 |
Why?
|
| Neutropenia | 1 | 2007 | 8 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 16 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 29 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 10 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 12 | 0.020 |
Why?
|
| Anemia | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cisplatin | 1 | 2007 | 25 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 252 | 0.010 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 13 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 10 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 15 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 817 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 68 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 76 | 0.010 |
Why?
|
| Bleomycin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Teniposide | 1 | 2004 | 1 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2004 | 2 | 0.010 |
Why?
|
| Leukopenia | 1 | 2004 | 4 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 2004 | 2 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 15 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 42 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 61 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 84 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 7 | 0.010 |
Why?
|
| Granulocytes | 1 | 2003 | 6 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 12 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 30 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 57 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 290 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2003 | 35 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 90 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 157 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 1049 | 0.010 |
Why?
|